BRIUMVI nearing $1B annual revenue with SC formulation and indication expansions as the growth ceiling test

Bull

Phase 1 PK/PD data showing GMR of 1.21 for quarterly dosing with a lower 90% CI bound of 1.15 provides strong statistical confidence that the Phase 3 trial will confirm non-inferiority, enabling a clean sBLA filing. A quarterly SC formulation would reduce infusion center dependency, broaden prescriber base to office-based neurologists, and directly counter the convenience profile of oral and home-administered MS therapies. Approval and launch of SC BRIUMVI could meaningfully accelerate new patient starts and improve adherence, supporting revenue growth beyond the $950M 2026 base.

Bear

Phase 3 SC bioequivalence results could fall outside the pre-specified equivalence margins due to inter-patient PK variability at the population level, despite favorable Phase 1 signals, delaying or blocking an sBLA filing. Local injection-site reactions observed in ~21% of Phase 1 patients with systemic reactions could worsen at scale, raising safety concerns that complicate the regulatory pathway or limit commercial uptake. Competing SC or oral anti-CD20 and TYK2 inhibitor programs, including envudeucitinib from Alumis (ALMS) and PIPE-307 from Contineum Therapeutics (CTNM), could erode new patient share before SC BRIUMVI reaches the market.